Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.
Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations.
A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults.
Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain.
New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144.
Extremely low viral reservoir in treated chronically HIV-1-infected individuals.
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
New emerging targets in cancer immunotherapy: the role of neoantigens.